Business Context and Reporting Period
Company: ILLUMINA, INC.
Filing Type: Form 10-Q (Quarterly Report)
Reporting Period: Three and nine months ended October 3, 2004.
Business Overview: Illumina develops tools for large-scale analysis of genetic variation and function, including oligonucleotides, genotyping systems (BeadLab, BeadStation), and SNP genotyping services. The company is heavily involved in the International HapMap Project funded by the National Institutes of Health (NIH).
Key Financial Metrics
| Metric (in thousands) | 3 Months Ended Oct 3, 2004 | 9 Months Ended Oct 3, 2004 | 9 Months Ended Sep 28, 2003 |
|---|---|---|---|
| Total Revenue | $13,512 | $35,800 | $17,294 |
| Net Loss | $(2,026) | $(9,472) | $(23,063) |
| Net Loss Per Share (Basic/Diluted) | $(0.05) | $(0.27) | $(0.72) |
| Gross Margin (Product & Service) | 73% | 72% | 56% (9 months) |
| Cash and Cash Equivalents | $54,322 | $54,322 | $9,989 |
| Total Assets | $92,072 | $92,072 | $99,234 |
| Stockholders' Equity | $68,729 | $68,729 | $47,388 |
Liquidity: As of October 3, 2004, the company held approximately $66.5 million in cash, cash equivalents, and investments (including $12.2 million in restricted cash/investments). Management expects current resources to fund operations for at least 24 months.
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 64% year-over-year for the nine-month period ($35.8M vs. $17.3M). Product revenue was the primary driver, rising 183% due to sales of BeadStation systems and consumables.
- Profitability Improvement: Net loss narrowed significantly to $9.5 million for the nine months ended Oct 3, 2004, compared to $23.1 million in the prior year period. This improvement was aided by a $1.5 million gain from a litigation settlement.
- Balance Sheet Restructuring: The company sold its San Diego land and buildings for $42.0 million and leased them back. This transaction resulted in $15.5 million in net cash proceeds and the payoff of $25.2 million in long-term debt. Consequently, long-term debt was eliminated from the balance sheet.
- Expense Increases: Selling, general, and administrative (SG&A) expenses increased 40% year-over-year for the nine-month period ($19.3M vs. $13.8M), driven by higher sales and marketing personnel costs and legal expenses.
Guidance, Outlook, and Risks
- Outlook: Management expects to continue incurring net losses through the end of 2004. Revenue growth is anticipated to be driven by the commercial launch of whole-genome genotyping and gene expression arrays, which are expected to offset the decline in NIH HapMap grant revenue as the project concludes in late 2004/early 2005.
- Legal Contingencies:
- Applied Biosystems: Settled in August 2004 with an $8.5 million payment, resulting in a $1.5 million gain and removal of a $10 million liability.
- Termination-of-Employment Lawsuit: A $7.7 million judgment from 2002 remains on appeal. The company has posted a $11.3 million surety bond, restricting approximately $12.5 million in marketable securities until the appeal is resolved.
- Affymetrix Litigation: Affymetrix filed a patent infringement suit in July 2004. The company intends to defend vigorously, but an unfavorable outcome could materially adversely affect operations.
- Risks: The company faces risks related to its early-stage commercialization, dependence on key personnel, intense competition, and the need for additional capital if revenue growth does not meet expectations. Approximately 55% of revenue comes from international customers, exposing the company to foreign currency and geopolitical risks.
Investor Verification Checklist
- Restricted Assets: Verify the status of the ~$12.5 million in restricted securities held as collateral for the employment lawsuit appeal bond.
- Revenue Concentration: Assess the impact of the winding down of the International HapMap Project (up to 30% of 2004 revenue) and the timeline for commercial product replacement.
- Legal Exposure: Monitor the progress of the Affymetrix patent infringement lawsuit and the final resolution of the employment lawsuit appeal.
- Cash Burn Rate: Confirm that the $66.5 million cash position is sufficient to cover operating losses and capital expenditures for the projected 24-month runway without dilutive equity raises.
- Debt Status: Confirm the complete payoff of the $26 million mortgage and the terms of the new sale-leaseback agreement.